These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 22042699)

  • 21. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma.
    Bard JD; Gelebart P; Anand M; Amin HM; Lai R
    Leukemia; 2008 Aug; 22(8):1595-603. PubMed ID: 18509351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
    Shi P; Lai R; Lin Q; Iqbal AS; Young LC; Kwak LW; Ford RJ; Amin HM
    Blood; 2009 Jul; 114(2):360-70. PubMed ID: 19423729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma.
    Wang P; Zhang JD; Wu F; Ye X; Sharon D; Hitt M; McMullen TP; Hegazy SA; Gelebart P; Yang J; Ma Y; Lai R
    Cell Signal; 2012 Oct; 24(10):1955-63. PubMed ID: 22743134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
    Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L
    Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
    Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
    Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathobiology of ALK+ anaplastic large-cell lymphoma.
    Amin HM; Lai R
    Blood; 2007 Oct; 110(7):2259-67. PubMed ID: 17519389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.
    Laimer D; Dolznig H; Kollmann K; Vesely PW; Schlederer M; Merkel O; Schiefer AI; Hassler MR; Heider S; Amenitsch L; Thallinger C; Staber PB; Simonitsch-Klupp I; Artaker M; Lagger S; Turner SD; Pileri S; Piccaluga PP; Valent P; Messana K; Landra I; Weichhart T; Knapp S; Shehata M; Todaro M; Sexl V; Höfler G; Piva R; Medico E; Ruggeri BA; Cheng M; Eferl R; Egger G; Penninger JM; Jaeger U; Moriggl R; Inghirami G; Kenner L
    Nat Med; 2012 Nov; 18(11):1699-704. PubMed ID: 23064464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK
    Hu L; Zhang X; Wang J; Wang S; Amin HM; Shi P
    Hematology; 2018 Jun; 23(5):284-290. PubMed ID: 29086626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.
    Wu F; Wang P; Zhang J; Young LC; Lai R; Li L
    Mol Cell Proteomics; 2010 Jul; 9(7):1616-32. PubMed ID: 20393185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Establishment and characterization of TK-ALCL1: a novel NPM-ALK-positive anaplastic large-cell lymphoma cell line.
    Sungwan P; Panaampon J; Kariya R; Kamio S; Nakagawa R; Hirozane T; Ogura Y; Abe M; Hirabayashi K; Fujiwara Y; Kikuta K; Okada S
    Hum Cell; 2024 Jul; 37(4):1215-1225. PubMed ID: 38755432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The t(2;5) in human lymphomas.
    Kadin ME; Morris SW
    Leuk Lymphoma; 1998 Apr; 29(3-4):249-56. PubMed ID: 9684923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK-driven lymphomagenesis.
    Redl E; Sheibani-Tezerji R; Cardona CJ; Hamminger P; Timelthaler G; Hassler MR; Zrimšek M; Lagger S; Dillinger T; Hofbauer L; Draganić K; Tiefenbacher A; Kothmayer M; Dietz CH; Ramsahoye BH; Kenner L; Bock C; Seiser C; Ellmeier W; Schweikert G; Egger G
    Life Sci Alliance; 2021 Feb; 4(2):. PubMed ID: 33310759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Next-generation sequencing identifies deregulation of microRNAs involved in both innate and adaptive immune response in ALK+ ALCL.
    Steinhilber J; Bonin M; Walter M; Fend F; Bonzheim I; Quintanilla-Martinez L
    PLoS One; 2015; 10(2):e0117780. PubMed ID: 25688981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.
    Mehrotra M; Medeiros LJ; Luthra R; Sargent RL; Yao H; Barkoh BA; Singh R; Patel KP
    Hum Pathol; 2014 Oct; 45(10):1995-2005. PubMed ID: 25128227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methotrexate significantly induces apoptosis by inhibiting STAT3 activation in NPM-ALK-positive ALCL cells.
    Uchihara Y; Komori R; Tago K; Tamura H; Funakoshi-Tago M
    Biochem Pharmacol; 2019 Dec; 170():113666. PubMed ID: 31654627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
    Hsu FY; Johnston PB; Burke KA; Zhao Y
    Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.
    Marzec M; Halasa K; Liu X; Wang HY; Cheng M; Baldwin D; Tobias JW; Schuster SJ; Woetmann A; Zhang Q; Turner SD; Ødum N; Wasik MA
    J Immunol; 2013 Dec; 191(12):6200-7. PubMed ID: 24218456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.
    Piva R; Pellegrino E; Mattioli M; Agnelli L; Lombardi L; Boccalatte F; Costa G; Ruggeri BA; Cheng M; Chiarle R; Palestro G; Neri A; Inghirami G
    J Clin Invest; 2006 Dec; 116(12):3171-82. PubMed ID: 17111047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.
    Cussac D; Greenland C; Roche S; Bai RY; Duyster J; Morris SW; Delsol G; Allouche M; Payrastre B
    Blood; 2004 Feb; 103(4):1464-71. PubMed ID: 14563642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
    Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
    Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.